Events2Join

Phase III TRIDENT trial


Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields

A phase 3, global, randomized study, will evaluate TTFields therapy concomitant with RT/TMZ in patients ≥18 years of age (≥22 years in the US) with ...

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT ...

“TTFields therapy has played a critical role in the treatment of newly diagnosed glioblastoma for nearly a decade, and the TRIDENT trial ...

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor ...

TRIDENT is an international phase III randomized trial comparing standard RT with TMZ vs the triple combination of RT plus TMZ with concomitant TTFields.

TRIDENT - Glioblastoma Clinical Trial - Novocure Trials

The TRIDENT trial (also known as the “EF-32 trial”) is a randomized, controlled study, testing the safety and efficacy of Tumor Treating Fields (TTFields) from ...

CTNI-09. TRIDENT PHASE 3 TRIAL (EF-32): FIRST-LINE TUMOR ...

TRIDENT (EF-32; NCT04471844) is an international, pivotal, phase 3 randomized trial comparing triple-combination of TTFields/radiotherapy/ ...

Trident phase 3 trial (EF-32): first-line Tumor Treating Fields (TTFields

Glioblastoma: Clinical Research. Brain Tumor Research and Treatment. F-1106. Trident phase 3 trial (EF-32): first-line Tumor Treating Fields. (TTFields; 200 kHz) ...

Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor ...

Here we present a phase 3 study examining the efficacy and safety of TTFields therapy concomitant with RT/TMZ in patients with ndGBM.

First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial ...

Trident will enroll 950 newly diagnosed GBM patients who, after surgery or biopsy, are candidates for radiation therapy and temozolomide. The ...

CTNI-74. PHASE 3 TRIDENT TRIAL: CONCOMITANT RADIATION ...

TRIDENT is an international phase III randomized trial comparing standard RT with TMZ vs the triple combination of RT/TMZ with concomitant ...

A Study of Repotrectinib Versus Crizotinib in Participants With ...

... (TRIDENT-3) - CA127-1030. Updated: 22 October, 2024 | ClinicalTrials.gov. About This ... Trial Details. Phase 3. Phase. Gender(s). 18+. Age Range. 58. Location(s).

Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed ...

Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma. “TTFields therapy has played a critical role in the treatment of newly ...

Final Participant Registered in TRIDENT Phase 3 Glioblastoma Trial

The primary endpoint of the trial is overall survival, with secondary endpoints including progression-free survival, one-year and two-year ...

Repotrectinib Recruiting Phase 3 Trials for Non-Small Cell Lung ...

Repotrectinib Recruiting Phase 3 Trials for Non-Small Cell Lung Carcinoma Treatment ... (TRIDENT-3). Crizotinib (DB08865) · Repotrectinib (DB16826). Stay up-to- ...

Abstract CT258: EF-32 (TRIDENT): A pivotal randomized trial of ...

In the Phase 3 EF-14 trial, TTFields (200 kHz) plus temozolomide (TMZ) post-surgery and chemoradiation significantly increased survival of ...

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT ...

The TRIDENT clinical trial is a randomized, open-label study designed to enroll 950 adult patients with newly diagnosed GBM. Following maximal ...

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating ...

Businesswire 2024 - Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma open_in_new. "Novocure...announced that ...

ASCO® 2023 Insights: "Phase 3 TRIDENT Study (EF-32) | VuMedi

A video from Wenyin Shi (as part of Insights from 2023 ASCO® Annual Meeting), posted on Jun 8, 2023.

TRIDENT phase 3 study (EF-32): first-line Tumor Treating Fields ...

... Trials. TRIDENT phase 3 study (EF-32): first-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance ...

P11.33.B Tumour Treating Fields (TTFields; 200 kHz) with chemo ...

TRIDENT (EF-32; NCT04471844) is an international, phase 3 randomised trial comparing TTFields (200 KHz, ≥ 18 h/day)/RT/TMZ vs RT/TMZ alone.